New Drugs for Hepatitis C

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
In an interview with The Florida Times-Union, Andrew P. Keaveny, MD, medical director of liver transplantation at the Mayo Clinic in Jacksonville, FL, discussed the 2011 approval of the protease inhibitors telaprevir and boceprevir as part of a triple-therapy regimen for hepatitis C. He said that the standard treatment for hepatitis C, interferon and ribavirin, has a 40% to 60% chance of achieving sustained virologic response. By comparison, triple therapy including either of the newly approved protease inhibitors in addition to interferon and ribavirin, has a 70% chance of sustained virologic response.
 
Dr. Keaveny explained that the protease inhibitors represent a major advance because they directly attack replication of the hepatitis C virus, whereas interferon and ribavirin fight the virus indirectly. He added that the new drugs do have new side effects as well as significant potential interactions with other medications. He added that, while triple therapy may require treatment as short as 24 to 48 weeks, regular blood tests and clinician visits are required during this period to monitor the patient’s progress.
 
To listen to the interview, click here.
Related Articles
A Houston-based gang called the 5th Ward has been accused of burglarizing 18 pharmacies since January 2014.
The Ohio Northern University Raabe College of Pharmacy prepares students to become not only pharmacists, but also citizens.
Jade Megyeri, University of Colorado Skaggs School of Pharmacy student, talks about the most rewarding experience she has had in pharmacy school.
Jade Megyeri, University of Colorado Skaggs School of Pharmacy student, talks about what characteristics pharmacists should embody.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$